Injecting and sexual risk correlates of HBV and HCV seroprevalence among new drug injectors

Alan Neaigus, V. Anna Gyarmathy, Maureen Miller, Vera Frajzyngier, Mingfang Zhao, Samuel R. Friedman, Don Des Jarlais

Research output: Contribution to journalArticle

Abstract

We examine injecting and sexual risk correlates of hepatitis B (HBV) and hepatitis C (HCV) seroprevalence among new injecting drug users (IDUs) (age 18-30 years, injecting ≤6 years). Participants were interviewed/serotested (HIVab, HBVcAb, HCVab) in New York City, February 1999-February 2003. Gender-stratified, multivariate logistic regression was conducted. Participants (N = 259) were: 68% male; 81% white. Women were more likely to test HCV seropositive (42% versus 27%) and men HBV seropositive (24% versus 12%); HIV seroprevalence was low (3%). Among both men and women, HBV seropositivity was associated with ever selling sex, and HCV seropositivity with ever having had infected (HIV, HBV or HCV) sex partners (among those ever sharing injecting equipment). Among women only, HBV seropositivity was associated with ever having had infected sex partners (regardless of ever sharing injecting equipment), and HCV seropositivity with ≥300 lifetime drug injections. Among men only, HCV seropositivity was associated with ≥40 lifetime number of sex partners (among those never sharing injecting equipment). In this new IDU sample, HBV and HCV seroprevalence differed by gender and were considerably higher than HIV seroprevalence. Early interventions, targeting injecting and sexual risks and including HBV vaccination, are needed among new IDUs to prevent HBV, HCV and, potentially, HIV epidemics.

Original languageEnglish (US)
Pages (from-to)234-243
Number of pages10
JournalDrug and Alcohol Dependence
Volume89
Issue number2-3
DOIs
StatePublished - Jul 10 2007

Fingerprint

Seroepidemiologic Studies
Drug Users
HIV Seroprevalence
Pharmaceutical Preparations
Equipment and Supplies
HIV
Hepatitis C
Hepatitis B
Logistics
Sales
Vaccination
Logistic Models
Injections

Keywords

  • Drug injectors
  • HBV
  • HCV
  • HIV
  • Injecting risk
  • Sexual risk

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Injecting and sexual risk correlates of HBV and HCV seroprevalence among new drug injectors. / Neaigus, Alan; Gyarmathy, V. Anna; Miller, Maureen; Frajzyngier, Vera; Zhao, Mingfang; Friedman, Samuel R.; Des Jarlais, Don.

In: Drug and Alcohol Dependence, Vol. 89, No. 2-3, 10.07.2007, p. 234-243.

Research output: Contribution to journalArticle

Neaigus, Alan ; Gyarmathy, V. Anna ; Miller, Maureen ; Frajzyngier, Vera ; Zhao, Mingfang ; Friedman, Samuel R. ; Des Jarlais, Don. / Injecting and sexual risk correlates of HBV and HCV seroprevalence among new drug injectors. In: Drug and Alcohol Dependence. 2007 ; Vol. 89, No. 2-3. pp. 234-243.
@article{f5eb609b382d436dbdf3dbac4f4f38e0,
title = "Injecting and sexual risk correlates of HBV and HCV seroprevalence among new drug injectors",
abstract = "We examine injecting and sexual risk correlates of hepatitis B (HBV) and hepatitis C (HCV) seroprevalence among new injecting drug users (IDUs) (age 18-30 years, injecting ≤6 years). Participants were interviewed/serotested (HIVab, HBVcAb, HCVab) in New York City, February 1999-February 2003. Gender-stratified, multivariate logistic regression was conducted. Participants (N = 259) were: 68{\%} male; 81{\%} white. Women were more likely to test HCV seropositive (42{\%} versus 27{\%}) and men HBV seropositive (24{\%} versus 12{\%}); HIV seroprevalence was low (3{\%}). Among both men and women, HBV seropositivity was associated with ever selling sex, and HCV seropositivity with ever having had infected (HIV, HBV or HCV) sex partners (among those ever sharing injecting equipment). Among women only, HBV seropositivity was associated with ever having had infected sex partners (regardless of ever sharing injecting equipment), and HCV seropositivity with ≥300 lifetime drug injections. Among men only, HCV seropositivity was associated with ≥40 lifetime number of sex partners (among those never sharing injecting equipment). In this new IDU sample, HBV and HCV seroprevalence differed by gender and were considerably higher than HIV seroprevalence. Early interventions, targeting injecting and sexual risks and including HBV vaccination, are needed among new IDUs to prevent HBV, HCV and, potentially, HIV epidemics.",
keywords = "Drug injectors, HBV, HCV, HIV, Injecting risk, Sexual risk",
author = "Alan Neaigus and Gyarmathy, {V. Anna} and Maureen Miller and Vera Frajzyngier and Mingfang Zhao and Friedman, {Samuel R.} and {Des Jarlais}, Don",
year = "2007",
month = "7",
day = "10",
doi = "10.1016/j.drugalcdep.2007.01.003",
language = "English (US)",
volume = "89",
pages = "234--243",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "2-3",

}

TY - JOUR

T1 - Injecting and sexual risk correlates of HBV and HCV seroprevalence among new drug injectors

AU - Neaigus, Alan

AU - Gyarmathy, V. Anna

AU - Miller, Maureen

AU - Frajzyngier, Vera

AU - Zhao, Mingfang

AU - Friedman, Samuel R.

AU - Des Jarlais, Don

PY - 2007/7/10

Y1 - 2007/7/10

N2 - We examine injecting and sexual risk correlates of hepatitis B (HBV) and hepatitis C (HCV) seroprevalence among new injecting drug users (IDUs) (age 18-30 years, injecting ≤6 years). Participants were interviewed/serotested (HIVab, HBVcAb, HCVab) in New York City, February 1999-February 2003. Gender-stratified, multivariate logistic regression was conducted. Participants (N = 259) were: 68% male; 81% white. Women were more likely to test HCV seropositive (42% versus 27%) and men HBV seropositive (24% versus 12%); HIV seroprevalence was low (3%). Among both men and women, HBV seropositivity was associated with ever selling sex, and HCV seropositivity with ever having had infected (HIV, HBV or HCV) sex partners (among those ever sharing injecting equipment). Among women only, HBV seropositivity was associated with ever having had infected sex partners (regardless of ever sharing injecting equipment), and HCV seropositivity with ≥300 lifetime drug injections. Among men only, HCV seropositivity was associated with ≥40 lifetime number of sex partners (among those never sharing injecting equipment). In this new IDU sample, HBV and HCV seroprevalence differed by gender and were considerably higher than HIV seroprevalence. Early interventions, targeting injecting and sexual risks and including HBV vaccination, are needed among new IDUs to prevent HBV, HCV and, potentially, HIV epidemics.

AB - We examine injecting and sexual risk correlates of hepatitis B (HBV) and hepatitis C (HCV) seroprevalence among new injecting drug users (IDUs) (age 18-30 years, injecting ≤6 years). Participants were interviewed/serotested (HIVab, HBVcAb, HCVab) in New York City, February 1999-February 2003. Gender-stratified, multivariate logistic regression was conducted. Participants (N = 259) were: 68% male; 81% white. Women were more likely to test HCV seropositive (42% versus 27%) and men HBV seropositive (24% versus 12%); HIV seroprevalence was low (3%). Among both men and women, HBV seropositivity was associated with ever selling sex, and HCV seropositivity with ever having had infected (HIV, HBV or HCV) sex partners (among those ever sharing injecting equipment). Among women only, HBV seropositivity was associated with ever having had infected sex partners (regardless of ever sharing injecting equipment), and HCV seropositivity with ≥300 lifetime drug injections. Among men only, HCV seropositivity was associated with ≥40 lifetime number of sex partners (among those never sharing injecting equipment). In this new IDU sample, HBV and HCV seroprevalence differed by gender and were considerably higher than HIV seroprevalence. Early interventions, targeting injecting and sexual risks and including HBV vaccination, are needed among new IDUs to prevent HBV, HCV and, potentially, HIV epidemics.

KW - Drug injectors

KW - HBV

KW - HCV

KW - HIV

KW - Injecting risk

KW - Sexual risk

UR - http://www.scopus.com/inward/record.url?scp=34248525496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248525496&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2007.01.003

DO - 10.1016/j.drugalcdep.2007.01.003

M3 - Article

C2 - 17289298

AN - SCOPUS:34248525496

VL - 89

SP - 234

EP - 243

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - 2-3

ER -